Remove 2010 Remove Hospitals Remove Pharmaceutical Companies
article thumbnail

Teva appoints Eric Hughes as head of R&D and Chief Medical Officer

European Pharmaceutical Review

Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceutical companies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. He will be based out of Teva’s US headquarters in Parsippany, New Jersey. . Dr Hughes earned his MD and PhD at Yale School of Medicine.

article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

Interestingly, the 340B law was actually included in a veterans healthcare bill (the Veterans Health Care Act) that also established a separate drug pricing program for veterans hospitals. It also raised the DSH payment cap for some rural and small urban hospitals to 12%. 2006: Congress passed, and President George W.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovation in immuno-oncology: Leading companies in microbiota restoration therapy

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

article thumbnail

Innovation in targeted therapies: Leading companies in photodynamic cancer therapy drugs

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. In terms of application diversity, Merck is the top company, followed by GlycoMira Therapeutics and Vertex Pharmaceuticals.

article thumbnail

Innovation in immuno-oncology: Leading companies in T-cell culturing

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. Whilst Seattle Children's Hospital and Qurgen stand in second and third positions, respectively.

article thumbnail

Are microtaggants the key to making medicines smarter?

pharmaphorum

Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. In 2010 a report from the Department of Health estimated that unused medicine costs the NHS in England around £300 million each year. Reduce wastage.

article thumbnail

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Hospitals 105